William J. Link PhD - 15 Sep 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 15 Sep 2026
Net transaction value: -$979,744
SEC form: 4
Accepted by SEC: 17 Sep 2026, 16:22:42 UTC
Prior SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Sieckert, Attorney-in-Fact

Key filing fact

William J. Link PhD filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 17 Sep 2026.

Key facts

This page summarizes William J. Link PhD's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Sep 2026, 16:22.

Change

Previous filing in this sequence was filed on 29 Jun 2026.
Current net transaction value: -$979,744.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001228684 Primary reporting owner

LINK WILLIAM J PHD

Relationship: Director
Address: C/O TARSUS PHARMACEUTICALS, INC., 17700 LAGUNA CANYON ROAD, FLOOR 4, IRVINE
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS transaction

Common Stock

Options Exercise

Transaction value
Shares: +201
Change %: +0.19%
Price
Shares after: 106,987
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1

TARS transaction

Common Stock

Sale

Transaction value: $914,503
Shares: -11,675
Change %: -11%
Price: $78.33
Shares after: 95,312
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F2, F3

TARS transaction

Common Stock

Sale

Transaction value: $59,961
Shares: -759
Change %: -0.8%
Price: $79.00
Shares after: 94,553
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F2, F4

TARS transaction

Common Stock

Sale

Transaction value: $5,281
Shares: -66
Change %: -0.07%
Price: $80.01
Shares after: 94,487
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -201
Change %: -25%
Price: $0.000000^*
Shares after: 605
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 201
Exercise price
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F2

The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

Footnote F3

The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F6

RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.